Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden
· Delayed Price · Currency is SEK 5.60
+0.44 (8.53%)
Mar 9, 2026, 5:29 PM CET
Egetis Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 215.8 | 351 | 303.3 | 127.7 | 144 | Upgrade
|
| Cash & Short-Term Investments | 215.8 | 351 | 303.3 | 127.7 | 144 | Upgrade
|
| Cash Growth | -38.52% | 15.73% | 137.51% | -11.32% | -49.97% | Upgrade
|
| Accounts Receivable | 19.2 | 15.5 | 28.2 | 3.8 | 3.5 | Upgrade
|
| Other Receivables | 8.7 | 8.1 | 8.4 | 6.7 | 3.3 | Upgrade
|
| Receivables | 27.9 | 23.6 | 36.6 | 10.5 | 6.8 | Upgrade
|
| Inventory | 2.3 | 1 | 0.7 | 0.6 | 0.7 | Upgrade
|
| Prepaid Expenses | 7.5 | 4.1 | 4.4 | 8.2 | 1.3 | Upgrade
|
| Other Current Assets | 0.1 | 0.4 | 0.9 | 0.4 | 0.1 | Upgrade
|
| Total Current Assets | 253.6 | 380.1 | 345.9 | 147.4 | 152.9 | Upgrade
|
| Property, Plant & Equipment | 9.7 | 2.6 | 4.4 | 2.7 | 4.3 | Upgrade
|
| Long-Term Investments | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | Upgrade
|
| Other Intangible Assets | 2.2 | 3.2 | 4.3 | 5.4 | 6.5 | Upgrade
|
| Long-Term Deferred Tax Assets | 1.7 | 0.6 | - | - | - | Upgrade
|
| Long-Term Deferred Charges | 371.1 | 404.8 | 404.8 | 404.8 | 404.8 | Upgrade
|
| Other Long-Term Assets | - | 0.2 | - | - | - | Upgrade
|
| Total Assets | 639.1 | 792.3 | 760.2 | 561.1 | 569.3 | Upgrade
|
| Accounts Payable | 21.8 | 25.7 | 28.7 | 20 | 4.6 | Upgrade
|
| Accrued Expenses | 176.7 | 131 | 47.2 | 12.7 | 5.3 | Upgrade
|
| Current Portion of Long-Term Debt | 31.5 | 30.1 | 5.2 | - | - | Upgrade
|
| Current Portion of Leases | - | 2.5 | 2.2 | 1.6 | 1.5 | Upgrade
|
| Current Income Taxes Payable | 0.1 | 0.2 | 0.1 | - | - | Upgrade
|
| Other Current Liabilities | 10.8 | 14.7 | 20.5 | 15.1 | 27.8 | Upgrade
|
| Total Current Liabilities | 240.9 | 204.2 | 103.9 | 49.4 | 39.2 | Upgrade
|
| Long-Term Debt | 45 | 84.1 | 103.4 | - | - | Upgrade
|
| Long-Term Leases | 5.6 | 0.4 | 2.2 | 1.1 | 2.7 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 1.7 | 0.5 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 7.2 | 10.2 | 5.1 | 4.4 | 0.4 | Upgrade
|
| Total Liabilities | 300.4 | 299.4 | 214.6 | 54.9 | 42.3 | Upgrade
|
| Common Stock | 22.3 | 20.4 | 15.4 | 11.3 | 8.7 | Upgrade
|
| Additional Paid-In Capital | 2,228 | 2,058 | 1,780 | 1,428 | 1,263 | Upgrade
|
| Retained Earnings | -1,948 | -1,610 | -1,267 | -939.6 | -745.8 | Upgrade
|
| Comprehensive Income & Other | 36.9 | 24.9 | 16.7 | 6.1 | 1.3 | Upgrade
|
| Shareholders' Equity | 338.7 | 492.9 | 545.6 | 506.2 | 527 | Upgrade
|
| Total Liabilities & Equity | 639.1 | 792.3 | 760.2 | 561.1 | 569.3 | Upgrade
|
| Total Debt | 82.1 | 117.1 | 113 | 2.7 | 4.2 | Upgrade
|
| Net Cash (Debt) | 133.7 | 233.9 | 190.3 | 125 | 139.8 | Upgrade
|
| Net Cash Growth | -42.84% | 22.91% | 52.24% | -10.59% | -50.63% | Upgrade
|
| Net Cash Per Share | 0.36 | 0.75 | 0.73 | 0.64 | 0.78 | Upgrade
|
| Filing Date Shares Outstanding | 395.16 | 359.24 | 292.57 | 214.59 | 165.07 | Upgrade
|
| Total Common Shares Outstanding | 395.16 | 359.24 | 292.57 | 214.59 | 165.07 | Upgrade
|
| Working Capital | 12.7 | 175.9 | 242 | 98 | 113.7 | Upgrade
|
| Book Value Per Share | 0.86 | 1.37 | 1.86 | 2.36 | 3.19 | Upgrade
|
| Tangible Book Value | 336.5 | 489.7 | 541.3 | 500.8 | 520.5 | Upgrade
|
| Tangible Book Value Per Share | 0.85 | 1.36 | 1.85 | 2.33 | 3.15 | Upgrade
|
| Machinery | - | 0.1 | 0.3 | 0.2 | 0.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.